Clinical Trial Update: A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults [Phase 2]

View source ↗

Summary

Phase II trial assessing immunogenicity and reactogenicity of recombinant HIV-1 envelope vaccines in MF59 and Alum adjuvants in healthy adults; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• MN rgp120/HIV-1 in Alum adjuvant (rgp120)
• SF-2 rgp120 (CHO) in MF59 adjuvant (rgp120)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED